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Genomics and CSF analyses implicate thyroid hormone in 
hippocampal sclerosis of aging
Peter T. Nelson1, Yuriko Katsumata1, Kwangsik Nho2, Sergey C. Artiushin1, Gregory A. 
Jicha1, Wang-Xia Wang1, Erin L. Abner1, Andrew J. Saykin2, Walter A. Kukull3, Alzheimer’s 
Disease Neuroimaging Initiative (ADNI)4, and David W. Fardo1
1University of Kentucky, Lexington, KY, USA
2University of Indiana, Indianapolis, IN, USA
3University of Washington, Seattle, WA, USA
Abstract
We report evidence of a novel pathogenetic mechanism in which thyroid hormone dysregulation 
contributes to dementia in elderly persons. Two single nucleotide polymorphisms (SNPs) on 
chromosome 12p12 were the initial foci of our study: rs704180 and rs73069071. These SNPs were 
identified by separate research groups as risk alleles for non-Alzheimer’s neurodegeneration. We 
found that the rs73069071 risk genotype was associated with hippocampal sclerosis (HS) 
pathology among people with the rs704180 risk genotype (National Alzheimer’s Coordinating 
Center/Alzheimer’s Disease Genetic Consortium data; n=2,113, including 241 autopsy-confirmed 
HS cases). Further, both rs704180 and rs73069071 risk genotypes were associated with 
widespread brain atrophy visualized by MRI (Alzheimer’s Disease Neuroimaging Initiative data; 
n=1,239). In human brain samples from the Braineac database, both rs704180 and rs73069071 risk 
genotypes were associated with variation in expression of ABCC9, a gene which encodes a 
metabolic sensor protein in astrocytes. The rs73069071 risk genotype was also associated with 
altered expression of a nearby astrocyte-expressed gene, SLCO1C1. Analyses of human brain 
gene expression databases indicated that the chromosome 12p12 locus may regulate particular 
astrocyte-expressed genes induced by the active form of thyroid hormone, triiodothyronine (T3). 
This is informative biologically because the SLCO1C1 protein transports thyroid hormone into 
astrocytes from blood. Guided by the genomic data, we tested the hypothesis that altered thyroid 
hormone levels could be detected in cerebrospinal fluid (CSF) obtained from persons with HS 
pathology. Total T3 levels in CSF were elevated in HS cases (p<0.04 in two separately analyzed 
groups), but not in Alzheimer’s disease cases, relative to controls. No change was detected in the 
serum levels of thyroid hormone (T3 or T4) in a subsample of HS cases prior to death. We 
conclude that brain thyroid hormone perturbation is a potential pathogenetic factor in HS that may 
also provide the basis for a novel CSF-based clinical biomarker.
Corresponding Author: Peter T. Nelson MD PhD, Department of Pathology, Division of Neuropathology, Rm 311, Sanders-Brown 
Center on Aging, 800 S. Limestone Avenue, University of Kentucky, Lexington, KY 40536-0230, Tel: 859.218.3862, 
pnels2@email.uky.edu.
4See http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_DSP_Policy.pdf
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Introduction
Hippocampal sclerosis (HS), characterized by cell loss and astrocytosis in the hippocampus 
[53, 65], is a common finding at autopsy of old persons [14, 47, 65, 100]. HS pathology is 
not specific to a particular disease process, so the underlying condition is diagnosed 
according to other clinical and pathological manifestations [25, 29]. Here we focus on 
individuals with amnestic dementia in advanced old age, in whom both HS and comorbid 
TAR DNA-binding protein 43 (TDP-43) pathology, but not advanced Alzheimer’s-type 
plaques and tangles, are seen at autopsy [2, 3, 45, 64, 70, 97]. Terms previously used to 
describe these cases include HS-Aging, HpScl, and HS dementia [1, 4, 14, 64]. However, 
terminology that focuses on HS is suboptimal because extensive pathology (and/or atrophy) 
exists outside of the hippocampus in this condition [15, 40, 43, 68, 69], and the term HS is 
far more commonly applied in the scientific literature to a different disease category – 
epilepsy. Thus a new diagnostic term was required to facilitate progress in the field.
We proposed a descriptive designation, “Cerebral age-related TDP-43 with sclerosis” 
(CARTS) [66]. The new terminology reflects that there is a distinct disease that 
preferentially affects persons in advanced old age and TDP-43 pathology is a relatively 
specific marker. These characterizations were based on clinical-pathologic correlation, 
neuroimaging, and genetic data [66].
CARTS has a large impact on public health according to studies from multiple high-quality 
autopsy series [65, 66, 100]. The disease affects approximately 20% of persons in advanced 
old age [47, 64, 69, 101], and is associated with substantial cognitive impairment [11, 58, 
60]. A group-level neurocognitive profile for CARTS patients has been described [64] and 
replicated [11]. However, CARTS tends to be misdiagnosed in the clinical context as 
Alzheimer’s disease (AD) because of overlapping symptoms [11, 64, 74], so autopsy data 
are essential for accurate disease diagnosis. Although CARTS appears to be a brainwide 
disease [15, 40, 43, 68, 69, 73], retrospective analyses (including the current study) mainly 
recognize HS, in the appropriate context, for indicating CARTS-type pathology.
Research on CARTS is evolving rapidly, yet there is no validated therapeutic strategy or 
clinical biomarker. In structural neuroimaging studies, hippocampal atrophy was more 
severe in cases with CARTS-type pathology than in AD [19], and frontal lobe atrophy was 
discernible in a retrospective study [43]. In terms of pathogenesis, chronic cerebrovascular 
disease may contribute to CARTS, and, in addition or alternatively, pathogenetic factors may 
overlap with FTLD [23, 63, 65, 100, 101].
Gene variants associated with CARTS-type pathology may provide insights into the 
mechanisms underlying the disease. Single nucleotide polymorphisms (SNPs) associated 
with altered risk for CARTS-type pathology have been reported in the following four genes, 
in the chronological order of their discovery: granulin (GRN), transmembrane protein 106B 
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(TMEM106B), ATP-binding cassette, sub-family C, member 9 (ABCC9), and potassium 
calcium-activated channel subfamily M regulatory beta subunit 2 (KCNMB2) [4, 5, 22, 24, 
57, 61]. In contrast to AD, apolipoprotein E (APOE) alleles were not associated with altered 
risk for CARTS-type pathology [11, 47, 64, 94].
The first published genome wide association study using CARTS-type pathology as an 
endophenotype reported that two intronic SNPs in near-perfect linkage disequilibrium (LD) 
with each other (rs704178 and rs704180), in the ABCC9 gene, were associated with 
CARTS-type pathology [61]. For practical reasons, we refer to rs704180 hereafter. The 
association between rs704180 and CARTS-type pathology was confirmed in a separate 
group of subjects [67].
Studies from multiple research centers have implicated the region of the human genome 
where ABCC9 is located (chromosome 12p12; Fig. 1) in neurodegenerative conditions. Two 
main points have emerged: 1. Genomic markers in and near chromosome 12p12 were linked 
to dementia risk, particularly among APOE ε4-negative persons [16, 52, 75, 84]; and, 2. 
Specific SNPs near the ABCC9 gene were associated with altered risk for developing non-
AD neurodegenerative disease phenotypes [27, 73]. Notably, Roostaei and colleagues [80] 
discovered that a SNP (rs73069071), which is ~500 kilobase-pairs (kbp) away from ABCC9, 
is associated with a phenotype of brain atrophy out of proportion to Aβ amyloid deposition.
We hypothesized that SNPs in the ABCC9 genomic region have an impact on gene 
regulatory mechanism(s) relevant to CARTS. To gain insights into those mechanisms, we 
analyzed human subjects’ data across a variety of contexts. Genomics data from the AD 
Genetics Consortium (ADGC) were correlated with clinical and pathologic data from the 
National Alzheimer’s Coordinating Center (NACC) database [6, 7, 32, 59]. We also 
correlated genomics data from AD Neuroimaging Initiative (ADNI) with magnetic 
resonance imaging (MRI) scans to confirm that risk alleles are associated with brain atrophy. 
Additional databases were evaluated to query the association between the risk alleles and 
human brain gene expression. Finally, we assayed thyroid hormone (TH) levels in 
cerebrospinal fluid (CSF) and in serum samples from the University of Kentucky AD Center 
(UK-ADC) biobank. Collectively, these analyses and experiments implicated TH 
perturbations in CARTS.
Materials and Methods
Analyses were performed on data obtained from multiple sources (Table 1). Written 
informed consent was obtained at the time of enrollment and/or genetic sample collection, 
and protocols were approved by each participating study and the respective sites’ 
Institutional Review Boards (IRBs). For more information on the data sources and IRBs, 
please see Acknowledgments in Supplemental Material. The data sources were mostly 
public-domain data repositories that included genomics. For two of these resources – termed 
BrainCloud and NABEC – University of Kentucky IRB and data access applications were 
required through the database of Genotypes and Phenotypes (dbGaP; https://
www.ncbi.nlm.nih.gov/gap). In addition to in silico analyses, new experiments were also 
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performed using biosamples (CSF and sera) from patients followed and autopsied at the UK-
ADC.
Association between risk SNPs and human neurodegeneration
ADGC/NACC neuropathology data—The ADGC accrued genomics data from 29 
different AD Centers (ADCs) as described in detail previously [67]. Briefly, multiple 
iterations of SNP data [32, 44] were analyzed together with neuropathological and clinical 
data gathered through NACC [6]. Genomic data from ADGC were transferred from PLINK 
format, with subsequent analyses performed using R 3.3.1 [91]. NACC data were obtained 
from the Minimum Data Set, Uniform Data Set, and Neuropathology Data Set [6, 11]. 
Neuropathologic evaluations were performed according to center-specific protocols -- 
including whether neuropathologists studied left, right, or bilateral hippocampi -- and 
entered into a standardized format. Details of CARTS-type pathology case/control 
operationalization in NACC were described previously [11, 61, 67]. Briefly, all included 
individuals died after 80 years of age. FTLD-TDP, other FTLD subtypes, and prion 
pathology cases were excluded from the analyses. For persons that died after 2013, the most 
recent NACC neuropathology form (v10) was used (https://www.alz.washington.edu/
NONMEMBER/NP/npform10.pdf). For these subjects, HS pathology as defined previously 
[67] with addition of the “NPHIPSCL” parameter. More details on inclusion/exclusion 
numbers are reported in Supplemental Material.
ADNI neuroimaging data—Information about the research subjects, genotyping, scan 
methods, and statistical analyses for the correlation between genetics and neuroimaging data 
in ADNI were as described in detail previously [73]. Briefly, the study included non-
Hispanic Caucasians in order to limit the impact of population stratification on association 
analysis (removing 140 participants). Genotyping was performed using the Illumina 
Human610-Quad BeadChip for the ADNI-1 participants, and the Illumina HumanOmni 
Express BeadChip and Illumina Omni2.5M BeadChip for participants initially enrolled in 
ADNI-GO or ADNI-2. SNPs were imputed separately in each phase as the ADNI cohort 
used different genotyping platforms. Before the imputation, standard sample and SNP 
quality control procedures were performed as described previously [71]. T1-weighted brain 
MRI scans were acquired using a sagittal 3D MP-RAGE sequence following the ADNI MRI 
protocol [35]. As detailed in previous studies [73, 78], FreeSurfer V5.1 software was utilized 
to extract brain-wide MRI-based imaging endophenotypes and the SurfStat software 
package to perform an unbiased whole brain surface-based analysis applying a general linear 
model (GLM) approach. GLMs were developed using age at baseline, gender, years of 
education, intracranial volume (ICV), diagnosis at baseline, MRI field strength, and SNP as 
independent variables. In the whole brain surface-based analysis, the adjustment for multiple 
comparisons was performed using the random field theory correction method at a 0.05 level 
of significance.
Testing implications of chromosome 12p12 risk genotypes
Braineac data set analyses—Data were obtained from the Braineac website, (http://
caprica.genetics.kcl.ac.uk/BRAINEAC/), which used an experimental pipeline described in 
Refs [76, 92]. Data from the Braineac data set comprise gene expression data from 10 brain 
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areas (hippocampus, frontal cortex, temporal cortex, occipital cortex, substantia nigra, 
frontal white matter, thalamus, putamen, medulla, and cerebellum) from 134 autopsied 
individuals, probed with 1,231 Affymetrix Exon 1.0 ST microarrays, and the same persons’ 
SNPs were characterized using an Illumina Omni 1M Immunochip platform. For the current 
study, the downloaded genomic data were analyzed using R 3.3.1 [91] using base packages 
and, for testing SNP/gene expression associations, the MatrixEQTL package [86] was used.
Human brain cell type specific expression of ABCC9 and SLCO1C1—Data from 
laser capture microdissection experiments from human temporal neocortex, followed by 
single cell RNA sequencing, from Ben Barres’s laboratory [17], are available online using a 
searchable web interface (Table 1). For this resource, no additional data were downloaded or 
analyzed further.
Gene expression in human brain: associations between TH sensitivity, 
chromosome 12p12 SNPs, and correlation with ABCC9 and SLCO1C1 
expression—We tested whether astrocyte-expressed genes upregulated after exposure to 
triiodothyronine (T3) also showed gene expression that was correlated with SNPs that affect 
ABCC9 and SLCO1C1 expression. The genes upregulated after exposure to T3 in astrocytes 
were identified in mice cultured brain cells by Gil-Ibanez et al [28]. We hypothesized that 
there would be concerted expression of these genes in human brains. To test this hypothesis, 
genes enriched after T3 treatment among astrocyte-expressed genes were compared to 
astrocyte-expressed genes that were not shown to be enriched after T3 exposure. 
Specifically, we tested the 15 highly-expressed astrocyte genes that were the most enriched 
following T3 exposure (fold-change relative to controls) in the Gil-Ibanez study. Gene 
expression data were analyzed from four separate large data sets that contain high-quality 
human brain gene expression data, focusing on adult brains without end-stage AD. Those 
data sets were described by the terms Braineac, BrainCloud, Allen Brain Institute, and 
NABEC (see Table 1). All of the available specimens were included from these sources, 
with the following exceptions: in BrainCloud, only subjects older than 20 years of age at 
death were included (n=148 included from that cohort, all frontal cortex); the same 20 years 
of age cutoff was applied for NABEC (n=166 included from that cohort, all frontal cortex); 
and, for Allen Institute data, we excluded 17 cases with Braak neurofibrillary tangle (NFT) 
stage VI pathology, and used parietal and temporal cortex data (n=158 total samples from 90 
persons included from that cohort). When more than one transcript variant could have been 
selected referent to a given gene, we used the transcript that showed highest mean 
expression across all the samples.
The control (not shown to be induced by T3) astrocyte-expressed genes used for comparison 
were selected based on the most astrocyte-enriched genes from mice brain experiments, 
since the T3-enriched genes also were identified in mice brain cells. We used the searchable 
website http://web.stanford.edu/group/barres_lab/brain_rnaseq.html; Ref [102]. The criteria 
for selecting genes: those genes that were most enriched in astrocytes relative to neurons, 
oligodendrocytes (all types including progenitors), and microglia and had Fragments Per 
Kilobase of exon per Million fragments mapped (FPKM)>50.
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Testing thyroid hormone levels in CSF and sera
CSF samples were analyzed from research volunteers in the UK-ADC autopsy cohort. 
Details of UK-ADC recruitment criteria and clinical assessments have been described [62, 
83]. The focus of the current study was subjects with short postmortem interval (PMI) 
autopsy (<4hrs). To obtain CSF at autopsy, an 18-gauge cannula was inserted into the body 
of the lateral ventricle. The CSF was centrifuged to remove blood cells and particulate 
matter, pipetted into 1.5-ml polypropylene tubes, and stored immediately at −80°C. Serum 
samples were obtained using a 23 or 21 gauge needle during life and stored, without either 
heparin or ethylenediaminetetraacetic acid (EDTA), at −80°C. Pathological assessment 
methodology at the UK-ADC has been described in detail [18, 62, 77, 98]. The criteria for 
HS pathology were neuronal loss and astrocytosis in hippocampal CA1 and subiculum 
regions, not readily ascribable to another pathology such as abundant NFTs or localizable 
infarction [53].
For TH assays, Total Thyroxine (T4) and Total T3 enzyme immunoassay test kits (Aviva 
System Biology, San Diego, CA) were used. Besides those explicitly described below, no 
other samples were evaluated and no other analyses performed on the included samples. All 
assays were performed following the manufacturer’s protocols. Briefly, undiluted specimen 
samples and manufacturer-supplied standard solutions were loaded in triplicate into 
microtiter plate wells. Samples and enzyme-linked immunosorbent assay (ELISA) plates 
were processed blind to clinical and pathological information. Absorbance was measured at 
450 nm using the microtiter plate reader SpectraMax M3 (Molecular Devices Inc., 
Sunnyvale, CA). Calculation of T3 and T4 concentrations was accomplished using SoftMax 
Pro 5.4.1 program (Molecular Devices Inc., Sunnyvale, CA). Data were downloaded to 
Microsoft Excel, unblinded at that point, and GraphPad Prism 6 was used for statistical 
analyses.
Two groups of samples (both including controls) were designated “Cohort 1” and “Cohort 
2”, and these samples were analyzed on separate ELISA plates. Both cohorts were selected 
such that the groups with and without HS pathology would have comparable AD-type 
pathology (by Braak NFT stages [10]), PMI, cognitive status (final Mini-Mental State Exam 
[MMSE] scores), and length of time the samples were stored in the −80°C freezer before 
being analyzed in the current study. These cohorts were non-overlapping and each 
comprised 26 different persons’ CSF, reflecting the number of samples that could be 
assessed in a single 96-well ELISA plate if the samples were analyzed in triplicate along 
with the manufacturer supplied standard samples. A third ELISA plate was analyzed to 
assess serum levels of both T3 and T4 from individuals in Cohort 1 (blood having been 
drawn prior to death), and a subset of the CSF results from the same group.
Research subjects were not included into, nor excluded from, the study based on clinical 
thyroid function, and selection was blind to clinical thyroid status. However, after the ELISA 
analyses were performed, a retrospective database search was performed to determine the 
status of diagnosed thyroid disease in research subjects from Cohort 1 and Cohort 2. Three 
different parameters were obtained: “Self-reported thyroid disease”, derived from a 
questionnaire that the person and/or caregiver filled out, indicating the individual had either 
hypothyroidism or hyperthyroidism diagnosed while being followed in the longitudinal 
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cohort; “Hypothyroid medicine”, which indicated the person was taking either Synthroid or 
some other form of L-thyroxine; and, “Hyperthyroid medicine”, which indicated the person 
was taking methimazole, propylthiouracil, and/or Tapazole. Within each cohort, chi-square 
tests were used to assess equivalence between cases with and without HS pathology with 
regard to thyroid disease and medication use.
Results
Testing association between risk SNPs and human neurodegeneration
ADGC/NACC neuropathology results—We first tested whether rs73069071 was 
associated with HS pathology in a cohort of older (≥80 year old at death) individuals in the 
NACC neuropathology data set with ADGC genomic characterization. We had previously 
identified that rs704180 is associated with HS pathology in the NACC/ADGC cohort [61, 
67], and here the data included information on 138 additional subjects (27 with HS 
pathology) who had died after 2013 and who were not included in prior analyses. In the 
overall cohort (n=2,113), rs73069071 risk genotypes (CC or CT) were associated with HS 
pathology among individuals with the rs704180 risk genotype (AA), p=0.023 (Table 2).
ADNI neuroimaging results—We next tested whether the SNPs rs73069071 and 
rs704180 (independent of rs73069071) were associated with brain surface atrophy detectable 
by structural MRI in older adults from the ADNI cohort (Fig. 2). In the 1,239 included 
participants, the average age at scan was 73.8 years, percentage of participants with APOE 
ε4 allele was 46.0%, and percentage of female participants was 42.7%. The risk genotypes 
for rs73069071 were CC and CT; minor allele frequency (MAF) was 11.8%. The risk 
genotype for rs704180 was AA; MAF was 48.7%. The assumed models of mode of 
inheritance were derived from the published literature [5, 67]. Gene variation at both 
rs73069071 and rs704180 SNPs was associated with widespread brain atrophy as quantified 
using MRI. Consistent with the pathology results from NACC/ADGC (above), the 
comparison of brain atrophy among individuals with rs704180 A_A genotype between those 
with and without the rs73069071 risk (C) allele shows that individuals with both risk 
genotypes have more atrophy in the medial temporal lobes (arrowheads in Fig. 2c). No 
associations were observed between brain atrophy and the non-risk alleles of these SNPs at 
the same statistical threshold (data not shown).
Testing implications of risk SNPs on human brain gene expression
Analyzing the association between chromosome 12p12 SNPs and gene 
expression—The Braineac website (Table 1) identifies the SNP with the strongest 
associations with expression of ABCC9 transcripts across all specimens; this was 
rs4148651, an intronic ABCC9 SNP. The National Institutes of Health/National Cancer 
Institute-sponsored search engine “LDlink” (Table 1) was used to test whether any of the 
three SNPs (rs704180, rs73069071, and rs4148651; Fig. 1) tend to show allelic association 
due to linkage, i.e. are in LD. According to this database, surveyed using “All populations”, 
rs704180 and rs4148651 were in LD, albeit relatively weakly at D’=0.44, r2=0.14. Neither 
rs4148651 nor rs704180 were in LD with rs73069071.
Nelson et al. Page 7
Acta Neuropathol. Author manuscript; available in PMC 2017 December 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
In the Braineac data set, which had the greatest sample size with 1,231 microarrays 
included, all three SNPs were associated with ABCC9 gene expression (Table 3). For both 
rs704180 and rs73069071, there was a consistent pattern noted as shown on Fig. 3: both 
SNPs were associated with the expression of multiple different ABCC9 exons (associated at 
p<0.05 were 28 probes for rs704180, 35 probes for rs73069071). The SNP rs73069071 was 
associated with gene expression of two additional chromosome 12p12 genes, SLCO1C1 
(Table 3) and PDE3A (data not shown). In addition, rs4148651 was associated with altered 
expression of SLCO1C1 (Table 3). The interactions between the three SNPs (haplotypes) in 
association with gene expression is a complicated bioinformatics challenge that we will 
address in a separate manuscript. Since SLCO1C1 expression was associated with 
SLCO1A2 and ABCC9 SNPs, we focused on a hypothetical gene regulatory mechanism 
related to SLCO1C1 function.
Testing human cell type specific expression of ABCC9 and SLCO1C1—A 
searchable web-based database indicated that both ABCC9 and SLCO1C1 were highly 
expressed in mature astrocytes in the human brain (Fig. 4). Further, each of the transcripts 
were expressed at relatively high levels (88th percentile for ABCC9, 98th percentile for 
SLCO1C1) in these human brain samples.
Assessing astrocyte-expressed genes in public access data sources—Since 
SLCO1C1 encodes an astrocytic TH transporter, we hypothesized that SNPs that change 
expression of SLCO1C1 could alter expression of downstream TH-regulated genes:
Genes that had been identified as astrocyte-expressed and enriched after T3 treatment by 
Gil-Ibanez et al [28] showed gene expression that was associated with SNP status for 
rs4148651 and rs73069071 (Table 4). Further, those same genes showed expression that 
were relatively strongly correlated with both ABCC9 and SLCO1C1 in the human brain 
across four separate high-quality data sets. By contrast, other genes that were enriched in 
astrocytes, but are not known to be T3-sensitive, did not show gene expression that was 
strongly associated with chromosome 12p12 SNPs, and these genes also did not correlate as 
strongly with ABCC9 or SLOC1C1 in the human brain gene expression databases. Note that 
in contrast to the human brain expression data, the T3 responsiveness, and the astrocyte 
enrichment data, were both derived from published studies that used mice brain cells [17, 
102]. Overall, these data are compatible with the hypothesis that T3 hormone regulation in 
the brain is sensitive to chromosome12p12 SNPs, with relatively wide-ranging impact on 
astrocyte gene expression, spanning many chromosomes. In summary, the chromosome 
12p12 SNPs appeared capable of altering TH-mediated astrocytic gene expression.
Testing thyroid hormone levels in CSF and sera
To follow up on the neuropathology, neuroimaging, and genomics analyses, and because 
CSF has previously been shown to contain quantifiable TH [38, 82, 88], we tested whether 
CSF TH levels were changed in cases with autopsy-confirmed CARTS/HS. Six separate 
ELISA plates were used, three each for T3 and T4 analyses, and each of which allowed 26 
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test samples to be evaluated in triplicate along with the manufacturer-supplied samples used 
for generating the standard curves. Two different groups of samples, designated “Cohort 1” 
and “Cohort 2”, were evaluated (Table 5). In both groups, HS+ cases had lower cognitive 
status, approximately the expected amount of global cognitive impairment (operationalized 
by final MMSE scores) that is directly associated with HS pathology in this cohort [60]. 
Although characteristics for HS+ and HS− cases were similar within each cohort, the two 
cohorts had differing characteristics overall -- Cohort 2 had relatively less AD pathology, 
higher cognitive status before death, were older, and the samples were stored longer in the 
freezer before the TH assays were performed.
We first assessed whether the assays’ sensitivity and technical parameters (using ELISA to 
study banked CSF samples in this context) were acceptable (Supplemental Fig. 1). Detected 
levels of TH were within the dynamic range of the assay, as determined using the sample 
standards provided by the manufacturer. Further, there was not a substantial (at p<0.05 level 
of significance) variation in detected T3 or T4 levels associated with PMI, age at death, or 
years of storage in the freezer. There did seem to be technical variance between plate 
readings (change in slope of standard curve resulting in different average values) so we did 
not compare or combine results across different plate readings.
Results of the T3 assays of CSF are shown in Figs. 5 and 6. In both non-overlapping 
experimental cohorts, the levels of total T3 detected were increased in cases with HS 
pathology relative to controls (p=0.030 for Cohort 1, p=0.033 for Cohort 2, both using 
Student’s t-test, 2-tailed, assuming unequal variance). Detected total T4 levels were not 
different for HS+ and HS− cases (p=0.080 for Cohort 1, p=0.95 for Cohort 2). Neither T3 
nor T4 levels were changed in relation to AD pathology, with the caveat that the small 
sample sizes did not enable sufficient statistical power to detect modest differences.
We also evaluated total T3 and T4 levels from serum. These were obtained from a 
convenience subsample of the same research volunteers (Table 6). The serum samples were 
stored at −80°C after having been drawn while the patients were alive, on average 40.9 (HS
+) and 41.8 (HS− cases) months prior to death. In these experiments, a total of 16 serum 
samples (10 HS−, 6 HS+) were available, and were correlated with results for 10 CSF 
samples (5 HS−, 5 HS+) from Cohort 1. As expected, total T4 levels were higher in serum 
(~70 ng/ml) than in CSF (~30 ng/ml), whereas total T3 levels were higher in CSF (~20 
ng/ml) than serum (~8 ng/ml), p<0.0001 for these comparisons. These numbers are best 
interpreted relative to each other since these are not laboratory tests validated for these 
experimental contexts. In contrast to the CSF, where the T3 levels trended higher in the HS+ 
cases, the T3 levels trended slightly lower in the serum samples obtained during life among 
individuals with eventual autopsy-proven HS. However, only 5 HS+ and 5 HS− CSF 
samples were included on the ELISA plates for comparison to the serum results, so the trend 
did not reach statistical significance.
Results of a retrospective analysis of clinically-relevant thyroid function in persons in 
Cohort1 and Cohort 2 are shown in Table 7. One person (HS+ case in Cohort 2) had missing 
data. Two subjects had remote history of thyroid disease, no longer treated. Otherwise, chi-
square analyses did not indicate any differences between HS+ and HS− subjects in either 
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cohort. Those with reported thyroid disease tended to have thyroid hypofunction in this 
sample since almost all were taking L-thyroxine. Although not different between persons 
with and without HS pathology in this relatively small sample, it is notable that overall one-
third (17/51) of individuals in this series had clinically relevant thyroid disease.
We also investigated retrospectively the pathology on a single case in detail (Fig. 7). This 
individual was selected because ELISA results indicated high total T3 level in CSF although 
HS was not diagnosed at autopsy (see green arrows, Fig. 5b and Fig. 6b). The research 
subject was a woman who died at age 95 and who had a final MMSE score of 27, almost 17 
months prior to death. At her last clinic visit she was taking L-thyroxine for clinical 
hypothyroidism. Autopsy found minimal AD-type pathology and the brain was negative for 
phospho-TDP-43 pathology in the left hippocampus and left frontal lobe (Brodmann Area 
9). However, there was an area – apparently a micro-infarct – in the right hippocampus with 
cell loss and gliosis (Fig. 7b). We retrospectively immunostained the right hippocampus for 
phospho-TDP-43 (1D3 clone) and found stained structures compatible with incipient 
TDP-43 pathology (Fig. 7c). It is unknown how this pathology is mechanistically related to 
HS/CARTS but this case helps to demonstrate the complex nature of brain pathologies in 
advanced age.
In summary, T3 levels were increased in the CSF of pathologically confirmed HS+ cases 
relative to persons without HS pathology in samples from two separate groups. These 
experimental results seem specific since differences were not detected for T4 levels, nor in 
serum, nor in cases stratified by AD pathology. The total T3 and T4 assay results appear 
robust given the technical parameters that were evaluated.
Discussion
Analyses of genetic risk alleles on chromosome 12p12 led to studies that implicated TH 
perturbation in CARTS. Although we only performed direct experimental tests on biofluids 
from 52 human subjects (17 with HS pathology), our study also incorporated analyses of 
data in the public domain referent to thousands of other individuals. Thus, finding evidence 
of a novel pathogenetic mechanism in a deeply complex milieu was enabled by the efforts of 
innumerable research volunteers and fellow researchers.
We found that two SNPs that are within ~500kbp of each other on human chromosome 
12p12 (rs73069071 and rs704180) were both associated with brain atrophy, brain pathology, 
and expression of ABCC9. Further, gene variants in this region, which were associated with 
altered gene expression for both ABCC9 and SLCO1C1, could also be correlated with a 
larger group of TH responsive astrocyte-expressed genes. This effect was at least somewhat 
specific since astrocyte-expressed genes that were not T3-responsive did not correlate with 
ABCC9, SLCO1C1, or the SNPs. We hypothesize that TH plays a role in CARTS 
pathogenesis, and consistent with that, we found that total T3 levels were increased in CSF 
of HS cases relative to controls. This study may help begin to explain and reconcile 
phenomena previously thought unrelated – chromosome 12p relationship to dementia, 
genomics of CARTS, a role for astrocytes in hippocampal TDP-43 pathology, and TH 
dysregulation in dementia.
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Chromosome markers in and near human chromosome 12p12 have been implicated 
repeatedly in dementia risk. The marker D12S1057, located ~2.5 Mbp in the centromeric 
direction from ABCC9, was linked to presumed AD in multiple studies [52, 75, 79, 85]. 
Interestingly, the association was in some cohorts strongest among APOE ε4- individuals 
and was not apparent in a relatively younger cohort [99]. There are also specific SNPs in the 
chromosome 12p12 region that have been associated with neurodegenerative phenotypes 
(Fig. 1). For example, Furney et al [27] reported that rs10743430 (~50kb upstream from 
ABCC9) is associated with MRI-detected “entorhinal thinning”.
Within the region between ABCC9 and SLCO1C1 on human DNA are genes that are 
relatively highly expressed in glia and/or brain endothelial cells. The arrangement of these 
genes on the DNA is conserved across many species whose common ancestors lived >400 
million years ago. For example, in the Coelecanth fish Latimeria chalumnae, as in humans, 
between ABCC9 and SLCO1C1 genes are KCNJ8, GOLT1B, LDHB, SLCO1A2, and 
PYROXD1. The retained order and proximity of these genes during evolution raises the 
possibility of adaptive brain function(s), related to orchestrated gene regulation in that 
region. Since SLCO1C1 is the primary transporter of TH into astrocytes [9, 95], it is a 
credible hypothesis that modulating SLCO1C1 expression is one of the ways that brain TH 
is regulated.
TH has strong biologic impact on the central nervous system. Lack of TH from birth causes 
a maldevelopment syndrome (“cretinism”), with severe mental retardation and extensive 
white matter pathology [81]. This syndrome has become rare in developed countries with 
neonatal screening and salt iodination. In the adult mammalian brain, TH plays important 
roles in metabolic regulation and astrocyte biology [21, 56]. TH dysregulation has been 
implicated in dementia previously -- both hyperthyroid and hypothyroid states have been 
linked to dementia [20, 39, 50, 54, 90]. TH has previously been evaluated in CSF [38, 82, 
87, 88], with varying results, but was never previously tested in relation to CARTS-type 
pathology. Ultimately, although TH is a biologically powerful molecule, and dementia is a 
common clinical syndrome, there currently is poor understanding of how TH perturbations 
contribute to dementia.
Whereas much remains to be learned about the complex biology of TH in the brain, it has 
been established that astrocytes play important roles in brain TH function. Astrocytes help 
import T4 from blood, process the hormone (convert T4 into T3), and deliver T3 to neurons 
[8, 9, 37, 42, 55]. T3 has strong impact on the astrocytes themselves, apparently driving a 
more developmentally ‘mature’ phenotype via transcriptional regulation [28, 51, 93].
A topical question is: do astrocytes participate in the pathogenetic cascade in CARTS? 
TDP-43 pathology is a key component of the pathologic phenotype [3, 66]. Although 
TDP-43 pathology in CARTS is conspicuous within neurons and neurites [2, 34, 65], 
astrocytes may play an active role in the pathogenesis. In Alexander disease, a disorder 
caused by toxic upregulation of glial fibrillary acidic protein (GFAP), hippocampal TDP-43 
pathology is frequently comorbid with the stereotypical astrocytic pathology and 
leukodystrophy [96]. Lin et al [48] described that TDP-43 pathology can be present in 
astrocyte foot-processes in the hippocampus. Abundant GFAP protein was also found in a 
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urea-insoluble protein fraction isolated from HS+ subiculum—the same fraction that also 
contained pathologic TDP-43 protein [65].
The hypothesis that astrocytes play a pathogenetic role in CARTS is supported by the 
present study. A novel regulatory mechanism may involve an astrocytic “metabolic sensor”, 
ABCC9, and a metabolic transporter, SLCO1C1 (Fig. 7). The ABCC9 gene product detects 
low ATP levels, opening a K+ (“KATP”) channel which leads to altered intracellular Ca++ 
levels [63]. ABCC9 helps regulate vascular function [26, 89], and mutations in ABCC9 have 
been shown to cause “tortuous” cerebral blood vessels in a human neuroimaging series [46]. 
Both ABCC9 and SLCO1C1 have been cloned in separate studies from rat brain 
microvasculature [12, 41], and small blood vessel pathology in humans has been implicated 
in CARTS [33, 68, 69]. A dysregulated pathway related to metabolic signaling in small 
blood vessels could mediate between ischemic stress in the aged brain and downstream 
effects such as TDP-43 pathology.
Although the current study provides evidence for a novel pathogenetic mechanism in the 
human brain, there are also limitations and potential pitfalls. Biologic complexity must be 
factored into interpretation of our results, given how much is unknown currently about the 
aged brain, the relevant biochemical pathways, and the comorbid pathologies. The gathering 
of data and analyses from many different sources increased the possibility of false-positive 
discovery due to over-testing. We attempted to minimize this source of bias by focal 
hypothesis-testing as much as possible. A benefit of our approach is that analyses can be 
replicated by others since the data are in the public domain. Yet there is potential for our 
analytic results to be “true, true, and unrelated”. For example, the genomic risk factors may 
not be directly or indirectly related, in a biologic sense, to the CSF T3 perturbations seen in 
persons with HS pathology. Also, the T3 assay results may be explained by perturbations in 
TH carrier molecules (e.g., transthyretin). Despite these uncertainties, detected T3 levels in 
CSF represent a potential clinical test for CARTS, which is a common disease that currently 
lacks a valid biomarker. We did not attempt to assess TH status in clinical (lumbar puncture) 
CSF samples, nor from other brain diseases such as FTLD, or the important subset of brains 
that have minimal or no HS pathology but TDP-43 pathology is present [34, 60]. Finally, 
Roostaei et al [80] noted that rs73069071 is located within the IAPP gene which encodes the 
polypeptide amylin. Unlike the overlapping gene SLCO1A2, IAPP/amylin is not known to 
be expressed in the human brain, but amylin has been associated with dementia through a 
mechanism linked to diabetes [36]. We conclude that there are many intriguing research 
questions to be addressed in future work.
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Fig. 1. 
Depiction of the region of human DNA that includes ABCC9, SLCO1C1, and single 
nucleotide polymorphisms (SNPs) that have been associated with non-Alzheimer’s 
neurodegenerative disease phenotypes according to research from multiple different research 
centers. Note that SNPs rs704180 and rs73069071 are approximately 500kb from each other 
on chromosome 12p12. Another SNP evaluated in the current study, rs4148651, is the SNP 
most strongly associated with ABCC9 expression in the Braineac website (Table 1); the 
location of rs4148651 is indicated with the orange arrowhead. Specific citations (Refs) are 
Zou et al [103], Roostaei et al [80], Nelson et al [61, 67], Furney et al [72], and Nho et al 
[73]. Source for this graphic is https://genome.ucsc.edu/
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Fig. 2. 
Regional brain atrophy that is associated with variation in chromosome 12p12 SNPs in the 
ADNI cohort (n=1239) as detected by brain MRIs from living subjects. This study evaluated 
differences in brain volumes comparing those with and without the risk alleles, using 
methodology as previously described [73]. The regions of the brain where atrophy was 
associated with the risk allele are shown in shades of blue which indicate p value. Both 
rs73069071 (a) and rs704180 (b) SNPs were associated with widespread brain atrophy as 
quantified using MRI. The minor allele frequency for rs73069071 was 11.8% in this cohort, 
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and these cases were excluded from the analyses of rs704180 (b). Panel (c) shows that 
among persons with the rs704180 A_A genotype, comparing between those with and 
without the rs73069071 risk genotype (any C allele) shows that individuals with the 
rs73069071 risk genotype have more atrophy in the medial temporal lobes (red arrowheads).
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Fig. 3. 
“Braineac” website (Table 1) data enabled testing of expression levels of exons across the 
ABCC9 transcript. The microarray enabled quantification of the expression of the individual 
exons using 48 different probes referent to ABCC9 (Affymetrix Exon 1.0 ST microarray 
Probe ID#’s 3446921–3447003). The probes consistently showed expression changes that 
were associated with rs704180 (red circles) and rs73069071 (green circles) SNP status. The 
genome assembly used for this figure is Build 34 which relates directly to the probe set 
reference values.
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Fig. 4. 
Both ABCC9 and SLCO1C1 are relatively highly expressed in mature astrocytes in the 
human brain. These results indicate human brain cell type specificity of ABCC9 (a) and 
SLCO1C1 (b) expression in this publicly available website. The study design [17] involved 
laser capture microdissection of cells from “temporal lobe cortex” of humans, followed by 
RNA-seq, from Ben Barres’s laboratory.
Source: http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?
geneNameIn=abcc9
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Fig. 5. 
In two non-overlapping convenience samples (n=26 persons in each), T3 levels were 
increased in CSF obtained from cases with hippocampal sclerosis (HS) pathology (a, b show 
results of Cohort 1 and Cohort 2) relative to controls. Statistics were run with Student’s t-
test, 2-tailed, assuming unequal variance. Bars depict standard error of the mean. Each of the 
comparison groups were matched for age, overall cognitive status (final MMSE score before 
death), the degree of AD-type pathology, length of time the CSF sample was stored at 
−80°C, and the post-mortem interval. The number of the samples used in each assay cohort 
was determined by the number of samples that could be applied in triplicate in a single 
ELISA assay while also including a standard curve. The data point referent to Fig. 7 is 
shown with a green arrow.
Nelson et al. Page 24
Acta Neuropathol. Author manuscript; available in PMC 2017 December 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Fig. 6. 
T3 levels were not increased in CSF with increasing severity of Alzheimer’s disease (AD) 
pathology (a, b show results of Cohorts 1 and Cohort 2). In comparison with Cohort 1, 
Cohort 2 cases had on average less severe AD pathology but the HS and non-HS cases were 
still matched for various parameters including severity of AD pathology as operationalized 
with Braak NFT stages. Bars depict standard error of the mean. Data points related to 
individuals with autopsy-confirmed HS pathology are shown in red. The data point referent 
to Fig. 7 is shown with a green arrow.
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Fig. 7. 
The CSF sample that had the highest level of detected total T3 in Cohort 2 (green arrows in 
Figs. 5 and 6) was from the brain of a woman with clinical hypothyroidism (taking L-
thyroxine at last clinic visit), who died at age 95 with final MMSE score of 27, and who 
lacked frank hippocampal sclerosis pathology. Alzheimer’s disease-type pathology was 
minimal: Braak NFT stage II, Thal Aβ stage 1, with no neuritic amyloid plaques. Phospho-
TDP-43 pathology was not identified in left hippocampus or frontal lobe. However, there 
was an area in the right hippocampus with cell loss and astrocytosis presumed to represent a 
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microinfarct (arrow in panel a, boxed area shown at higher magnification in panel b). In this 
section, small foci of phospho-TDP-43 (P-TDP-43) immunoreactive structures were seen in 
CA1 (c). Hippocampal CA1 and dentate granule (dg) regions are indicated for orientation. 
Scale bars = 2mm (a) 300 µm (b), and 50 µm (c).
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Fig. 8. 
Cartoon depicts how ABCC9 and SLCO1C1 may participate in regulation of thyroid 
hormones (T3 and T4) in astrocytes. Highlighted areas of interest (black multi-point stars) 
that require further study include: 1. ABCC9 gene product (SUR2) may link metabolic 
needs and altered transcriptional signaling; 2. T4 transport into astrocytes (mediated by 
SLCO1C1 protein) may be affected by advanced old age, which often is attended by 
disrupted vasculature, increased oxidation, and various stressors; 3. T3-mediated gene 
expression regulation in astrocytes may change under conditions of stress or ischemia; 4. 
How T3 transport is regulated by SLCO1C1 and other transporters that are not astrocytic; 5. 
T3 transport from astrocytes into neurons and CSF, which may be altered by various 
stressors and/or aging itself. Increased T3 levels in CARTS cases’ CSF may have 
pathogenetic impact on neurons and/or synapses.
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Table 1
Data sources for the current study
Data Source
(alphabetic order)
Samples Primary
measurement/
source
Analytic
platform(s)
Website and source information, Ref#
Allen Brain Institute 90 adults
(no Braak
VI)
Parietal cortex
and temporal
cortex
RNA Seq http://aging.brain-map.org/rnaseq/
Alzheimer’s Disease
Genetics 
Consortium
(ADGC) and 
National
Alzheimer’s
Coordinating Center
(NACC)
2,113
autopsied
persons
Detailed
neuropathology
data
Illumina
Omni SNP
arrays, see
methods
https://www.alz.washington.edu/;
http://www.adgenetics.org/
Alzheimer’s Disease
Neuroimaging
Initiative (ADNI)
1,239 live
persons
Brain surface
measured with
MRI
Illumina
Omni SNP
arrays, see
methods
http://www.adni-info.org/
Barres Lab human
cerebral cortex
466 cells
from 8
human
adults, 4
embryos
Temporal
neocortex
RNA Seq
after laser
capture
micro-
dissection
http://web.stanford.edu/group/barres_lab/cgi-bin/geneSearch.py?geneNameIn=abcc9;
Ref [17]
Barres Lab with cell
type enrichment
Mice brain
cells
Cell types
enriched from
cerebrocortical
brain areas
RNA Seq
after cell
enrichment
http://web.stanford.edu/group/barres_lab/brain_rnaseq.html;
Ref [102]
BrainCloud 148 adults
(>20y.o.
cutoff)
Frontal Cortex Affymetrix
Exon 1.0 ST
Array,
Illumina
Omni 1M
Immunochip
http://braincloud.jhmi.edu/; Ref [13];
dbGaP accession #:
phs000417.v2.p1
Braineac 134 adults 10 brain areas
(see Methods)
Affymetrix
GeneChip,
Exon 1.0 ST
Array
http://caprica.genetics.kcl.ac.uk/BRAINEAC/;
Refs [76, 92]
Gil-Ibanez et al, T3
impact on astrocyte
gene expression
T3-treated primary mice
cerebrocortical cells
RNA Seq Ref [28]
LDlink NCI/NIH site for search of linkage
disequilibrium between SNPs
http://analysistools.nci.nih.gov/LDlink/;
Ref [49]
North American
Brain Expression
Consortium
(NABEC)
166 adults
(>20y.o.
cuttoff)
Frontal Cortex Illumina
HT12v3 array
Refs [30, 31];
dbGaP accession #:
phs000249.v2.p1
U. Kentucky
AD Center autopsy
series
52
autopsied
persons
CSF and sera T3 and T4
assays
(ELISA)
See methods
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Table 2
NACC/ADGC data: Percentage of individuals who died ≥80years old, lacking frontotemporal lobar 
degeneration, with hippocampal sclerosis (HS) pathology, stratified by SNPs (n=2,113 autopsied individuals 
including 241 HS cases)
rs73069071
genotype
Number of HS
cases (%)
p-value
rs704180 risk
genotype (AA)
CC or CT
TT
23 (23.0)
63 (13.9)
0.023*
rs704180 non-risk
genotype (AG or GG)
CC or CT
TT
36 (9.6)
119 (10.0)
0.82
*
-With continuity correction, p=0.034
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Table 3
Testing the association between SNP status and gene expression, Braineac (n=1,231 gene expression 
microarrays, 134 SNP arrays, see Table 1): p-values
SLCO1A2 SNP ABCC9 SNPs
Gene rs73069071 rs704180 rs4148651
ABCC9 0.0067 0.011 5.3 × 10−7
SLCO1C1 0.0060 0.25 0.0031
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Table 4
Astrocyte-expressed genes in public access data sources: enrichment in cell culture after thyroid hormone (T3) 
treatment, association between gene expression and SNP status, and association with the gene expression of 
ABCC9 and SLCO1C1 in four different large human brain gene expression data sets
*
- From Gil-Ibanez et al [28]. Shown are the 15 astrocyte-expressed genes that were most upregulated following treatment of mouse cerebrocortical 
cells with triiodothyronine (T3) in culture, FPKM >10
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**
- See Table 1 for more information; each data set comprises a separate cohort with >100 human brain samples with gene expression profiling
***
- For comparison, the top 10 expressed astrocyte genes as determined to be expressed in mouse astrocytes (in comparison to Neuron, OPC, 
Newly Formed Oligodendrocyte, Myelinating Oligodendrocyte, Microglia) in http://web.stanford.edu/group/barres_lab/brain_rnaseq.htm
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Table 7
Parameters related to self-reported thyroid disease and thyroid related medications in Cohort 1 and Cohort 2, 
stratified by hippocampal sclerosis (HS) pathology
n
Self-reported
thyroid disease*
Y/N
Hypothyroid
medicine*
Y/N
Hyperthyroid
medicine*
Y/N
Cohort 1
HS+ 8 3/5 3/5 0/8
HS− 18 5/13 5/13 0/18
Cohort 2
HS+ 11 4/7 3/8 0/11
HS− 14 5/9 7/7 0/14
*
-See Methods for explanation
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